Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

EMERGENT BIOSOLUTIONS INC.

(EBS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Emergent BioSolutions Announces Initiation of Pivotal Phase 3 Study Evaluating the Safety and Immunogenicity of Its Single-Dose Chikungunya Vaccine Candidate, CHIKV VLP

10/15/2021 | 06:30am EST

Emergent BioSolutions Inc. announced the first participant dosed in its pivotal phase 3 study evaluating the safety and immunogenicity of the company’s investigational chikungunya virus (CHIKV) virus-like particle (VLP) vaccine candidate, CHIKV VLP, in a single dose. CHIKV VLP is the only VLP-based vaccine currently in clinical development for active immunization against chikungunya disease. The goal of this multi-center, randomized, double blind, placebo-controlled study is to evaluate the safety and immunogenicity of the CHIKV VLP vaccine candidate in healthy individuals aged 12 to 64 as well as to demonstrate the consistency of the chikungunya virus (CHIKV) serum neutralizing antibody (SNA) response across three manufactured vaccine candidate lots. The study will observe the CHIKV SNA response at day 22 as measured by geometric mean titer and seroresponse rate and will enroll at least 3,150 participants in up to 49 U.S. sites. The structure of the CHIKV VLP is nearly identical to the wild-type virus but does not pose a risk of replication. Studies have shown that in general, other VLP vaccines are highly immunogenic, safe, and typically elicit high titer neutralizing antibodies, which are needed to protect against chikungunya virus.i,ii There is currently no licensed vaccine, VLP or otherwise, to prevent chikungunya virus disease.


© S&P Capital IQ 2021
All news about EMERGENT BIOSOLUTIONS INC.
11/24Janssen COVID-19 vaccine plant in Baltimore gets Health Canada OK
AQ
11/24Canada clears import of J&J COVID-19 vaccine doses made at Emergent plant
RE
11/23Thinking about buying stock in Aptevo Therapeutics, Navitas Semiconductor, Berkshire Gr..
PR
11/22SiTime to Join S&P MidCap 400, Pushing Emergent BioSolutions to S&P SmallCap 600 From N..
MT
11/12EMERGENT BIOSOLUTIONS INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
11/11Emergent Biosolutions' Board Approves Repurchases of up to $250 Million Shares; Stock R..
MT
11/11Emergent BioSolutions Announces Stock Repurchase Program
AQ
11/11Emergent BioSolutions Inc. announces an Equity Buyback for $250 million worth of its sh..
CI
11/11Emergent BioSolutions Inc. authorizes a Buyback Plan.
CI
11/10Chardan Adjusts Price Target on Emergent Biosolutions to $75 From $92, Maintains Buy Ra..
MT
More news
Analyst Recommendations on EMERGENT BIOSOLUTIONS INC.
More recommendations
Financials (USD)
Sales 2021 1 689 M - -
Net income 2021 230 M - -
Net Debt 2021 371 M - -
P/E ratio 2021 9,87x
Yield 2021 -
Capitalization 2 265 M 2 265 M -
EV / Sales 2021 1,56x
EV / Sales 2022 1,39x
Nbr of Employees 2 200
Free-Float 88,6%
Chart EMERGENT BIOSOLUTIONS INC.
Duration : Period :
Emergent BioSolutions Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EMERGENT BIOSOLUTIONS INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 42,10 $
Average target price 57,40 $
Spread / Average Target 36,3%
EPS Revisions
Managers and Directors
Robert G. Kramer President, Chief Executive Officer & Director
Richard Scott Lindahl Chief Financial Officer, Treasurer & Executive VP
Fuad El Hibri Executive Chairman
Sharon M. Solomon Chief Information Officer & Senior Vice President
Karen L. Smith Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
EMERGENT BIOSOLUTIONS INC.-53.01%2 265
JOHNSON & JOHNSON1.16%420 557
ROCHE HOLDING AG15.70%334 662
PFIZER, INC.42.35%294 114
NOVO NORDISK A/S67.75%247 392
ELI LILLY AND COMPANY50.93%231 027